On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per day) CIV was available by prescription for the treatment of postpartum depression (PPD) for adults in the U.S., with product already at specialty pharmacies and delivered to patients.

ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.